Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced its participation in two upcoming investor conferences:
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
